Trial Profile
Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 26 Mar 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Mar 2010 Planned end date (1 Sep 2008) added as reported by ClinicalTrials.gov.